In a phase 2a study in patients with moderate-to-severe CD who experienced treatment failure or were intolerant to ≥ 1 anti-TNFα agent, clinical improvement as measured by clinical response (decrease in Crohn’s Disease Activity Index [CDAI]) was observed after 8 weeks of brazikumab treatment [20]. Here, TNF is linked to Cowden disease.